Peripheral T-Cell Lymphoma in 2013

Slides:

Advertisements

Similar presentations

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.

Advertisements

Gopal AK et al. Proc ASH 2013;Abstract 4382.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, :00 PM.

Belinostat, a Novel Pan-Histone Deactylase Inhibitor (HDACi), in Relapsed or Refractory Peripheral T-Cell Lymphoma: Results from the BELIEF Trial1 Belinostat.

LaCasce A et al. Proc ASH 2014;Abstract 293.

ECHELON-2: Phase 3 Trial of Brentuximab Vedotin and CHP versus CHOP in the Frontline Treatment of Patients (Pts) with CD30+ Mature T-Cell Lymphomas (MTCL)1.

Advances in the treatment of T cell lymphomas Yok-Lam Kwong Department of Medicine Queen Mary Hospital.

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Complete remissions with SGN-35 weekly dosing: a phase 1 dose-escalation study in relapsed/refractory HL or systemic ALCL patients Nancy L Bartlett,

MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.

Results from a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy 1 Final.

FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

DLBCL with less than PR to second line therapy… Correcting a Misconception…. Koen van Besien, MD Weill Cornell Medical College, NY.

High Response Rates to Crizotinib in Advanced, Chemoresistant ALK+ Lymphoma Patients 1 Crizotinib in Advanced, Chemoresistant Anaplastic Lymphoma Kinase-Positive.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

Bortezomib (BTZ) and Panobinostat (PAN) Combination Is Effective in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) or NK/T-Cell Lymphoma.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Steven M. Horwitz, MD Assistant Attending Physician Lymphoma Service Department of Medicine Memorial Sloan-Kettering Cancer Center New York, New York Clinical.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Survey summary PTCL clinical practice recommendations

A new possible conditionning regimen before Autologous Stem Cell Transplantation for refractory high-grade lymphoma Z-BeEAM (Ibritumomab tiuxetan, Bendamustine,

: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma

Campos M et al. Proc EHA 2013;Abstract B2009.

Non-Hodgkin’s Lymphoma

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Campos M et al. Proc EHA 2013;Abstract B2009.

19-28z CAR T-Cell Efficacy and Toxicity in Adults With R/R B-Cell ALL

Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma New Findings in Hematology: Independent Conference Coverage of ASH.

Reeder CB et al. ASCO 2009; Abstract (Poster)

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Slide set on: McCarthy PL, Owzar K, Hofmeister CC, et al

Oki Y et al. Proc ASH 2013;Abstract 252.

KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.

Fujiwara H et al. Proc ASH 2015;Abstract 181.

T Cell Lymphomas : Treatment Strategies

Post-autologous Transplant Therapy for Hodgkin Lymphoma

Updates in Hodgkin Lymphoma

Hot Topics in Lymphoma Supportive Care

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Advances in Lymphoma.

R-CHOP Stem Cell Transplantation for Follicular Lymphoma

Updates in Follicular Lymphoma

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Treatment Decisions in Chemorefractory Follicular Lymphoma

Ansell SM et al. Proc ASH 2012;Abstract 798.

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

The role of allogeneic transplantation in peripheral T-cell lymphomas

Stephen Ansell, MD, PhD Mayo Clinic

Emerging Frontline Treatments for Patients With Hodgkin Lymphoma

Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

New ELN Recommendations

FDA-Approved PI3K Inhibitors for CLL and FL

Emerging Regimens in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Anas Younes, M.D. Memorial Sloan Kettering Cancer Center

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Advani RH et al. Proc ASH 2011;Abstract 443.

Presented by: Dr.Naser Shagerdi Esmaeli

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

Foroud shahbazi Pharm.D

Lymphoma in Pediatrics 23rd Nov 2018

Changing Paradigms in Relapsed/Refractory Indolent NHL

by Lapo Alinari, and Kristie A. Blum

Presentation transcript:

Peripheral T-Cell Lymphoma in 2013

Program Goal

WHO 2008 Classification of Mature T/NK-Cell Neoplasms

Use of the Term PTCL

PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas

International PTCL Study: Major NHL Types by Region

Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL

ALK and ALCL

Outcomes by PTCL Subtypes

Prognostic Indices for PTCL

Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a Prospective Multicenter Study

CHOP: First-line Treatment of PTCL

Alemtuzumab (A) + Chemotherapy First-line treatment of PTCL

CHOP+ and Non-CHOP: First-line Treatment of PTCL

Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free Survival of Younger Patients

Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival of Younger Patients (cont)

Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival

Prognostic Factors in Trials of ASCT in First Remission

ICE and Planned ASCT for Relapsed/ Refractory T-Cell Lymphoma: PFS From ICE

CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in CR1

Retrospective Analyses of Allogeneic Stem-Cell Transplantation for PTCL

Approved Agents in Relapsed/Refractory PTCL

PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients (n = 111)

Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)

Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL

Brentuximab Vedotin in Relapsed ALCL: Toxicities

Brentuximab: Best Clinical Response by Disease Diagnosis

Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells

Front-line Therapy: Study Design (Combination Therapy Arms)

Front-line Therapy: Best Response by Disease Diagnosis

Bendamustine in T-Cell Lymphoma (BENTLY Trial)

Lenalidomide in Relapsed/Refractory TCL: Phase 2 Trial

Belinostat: PTCL Response Assessed by Central Review

Belinostat: Response Rate by CPRG Lymphoma Diagnosis

Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)

MLN8237: Response (PR + CR) by Histology

IPI-145: A PI3K-δ,γ Inhibitor

Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma

Mogamulizumab (KW-0761) Anti-CCR4 Monoclonal Antibody

Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)